Nabi Biopharmaceuticals, Inc.

Nabi

Glaxosmithkline Biologicals Sa

United States of America As Represented by the Secretary, Dhhs Office of Technology Transfer, National Institutes of Health

Sofiane Ennifar

Ali Ibrahim Fattom

Robert B Naso

Zuzana Kossaczka

Kimberly L Taylor

Scott Winston

James Terrill

Jawad Sarwar

Steve Fuller

Novel hapten-carrier conjugates are capable of inducing the production of antibodies, in vivo, that specifically bind to nicotine. These conjugates comprise a nicotine hapten conjugated to an immunogenic carrier protein. The novel conjugates preserve the chirality of nicotine in its native (S)-(&#x2212;) state, and have good stability properties. The conjugates are useful in formulating vaccines for active immunization, that are used to prevent and treat nicotine addiction. The antibodies raised in response to the nicotine hapten-carrier conjugate are used for passive immunization. These antibodies are administered for prevention and treatment of nicotine addiction.

Hapten-carrier conjugates for treating and preventing nicotine addiction

A method of preventing or treating staphylococcal bacterial infection in an individual is disclosed. A vaccine based on a conjugate of PS1 polysaccharide antigen can be used for active protection in individuals who are to be subjected to conditions that place them at immediate risk of developing a bacterial infection, as would be case in the context of a catheterization or a surgical procedure. Alternatively, antibodies raised in response to the antigen can be used to treat or to provide passive protection to individuals. The method can be used in a population of patients at risk for infection by various species ofor various types of

Method of protecting against staphylococcal infection

The present invention relates methods for reducing the adverse effects of nicotine. This application describes the use of nicotine carrier conjugates in decreasing the toxic effects of nicotine on a fetus.

Methods for decreasing the toxic effects of nicotine on fetuses in pregnant women

A high yielding and short process for preparing the 3'-aminomethylnicotine hapten of general formula I permits the isolation of the hapten in very pure quantities. The process can be adapted for the synthesis of a single stereoisomer or mixtures of stereoisomers, such as the stereoisomers trans-Ia and trans-Ib: Compounds of general formula I are useful for the preparation of hapten-carrier conjugates in the treatment of nicotine addiction.

Method for making nicotine hapten

Novel hapten-carrier conjugates are capable of inducing the production of antibodies, in vivo, that specifically bind to nicotine. These conjugates comprise a nicotine hapten conjugated to an immunogenic carrier protein. The novel conjugates preserve the chirality of nicotine in its native (S)-(&minus;) state, and have good stability properties. The conjugates are useful in formulating vaccines for active immunization, that are used to prevent and treat nicotine addiction. The antibodies raised in response to the nicotine hapten-carrier conjugate are used for passive immunization. These antibodies are administered for prevention and treatment of nicotine addiction.

Growing community of inventors

Silver Spring, MD, United States of America

Sofiane Ennifar